BACKGROUND: African American accrual to prevention trials at rates representative of the disease burden experienced by this population requires additional resources and focused efforts. PURPOSE: To describe the rationale, context, and criteria for selection of sites that received Minority Recruitment Enhancement Grants (MREGs) to increase African American recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). To determine if African American accrual was higher among the 15 MREG sites when compared with similar nonawarded sites. METHODS: Changes in African American accrual at sites that received MREGs are compared with changes in a group of 15, frequency-matched, nonawarded sites using a quasi-experimental, post hoc analysis. Successful and unsuccessful recruitment strategies reported by the MREG sites are described. RESULTS: The increased number of African American participants accrued per month at MREG sites post-funding was higher than the change at comparison sites by a factor of 3.38 (p = 0.004, 95% CI: 1.51-7.57). An estimated 602 additional African American participants were recruited at MREG sites due to MREG funding, contributing to the overall 14.9% African American recruitment. Successful recruitment strategies most reported by MREG sites included increasing staff, transportation resources, recruiting through the media, mailings, and prostate cancer screening clinics during off-hours. LIMITATIONS: Comparison sites were chosen retrospectively, not by randomization. Although comparison sites were selected to be similar to MREG sites with regard to potential confounding factors, it is possible that unknown factors could have biased results. Cost-effective analyses were not conducted. CONCLUSIONS: MREG sites increased African American accrual in the post-funding period more than comparison sites, indicating MREG funding enhanced the sites' abilities to accrue African American participants. Targeted grants early in the accrual period may be a useful multi-site intervention to increase African American accrual for a prevention study where adequate African American representation is essential.
BACKGROUND: African American accrual to prevention trials at rates representative of the disease burden experienced by this population requires additional resources and focused efforts. PURPOSE: To describe the rationale, context, and criteria for selection of sites that received Minority Recruitment Enhancement Grants (MREGs) to increase African American recruitment to the Selenium and Vitamin ECancer Prevention Trial (SELECT). To determine if African American accrual was higher among the 15 MREG sites when compared with similar nonawarded sites. METHODS: Changes in African American accrual at sites that received MREGs are compared with changes in a group of 15, frequency-matched, nonawarded sites using a quasi-experimental, post hoc analysis. Successful and unsuccessful recruitment strategies reported by the MREG sites are described. RESULTS: The increased number of African American participants accrued per month at MREG sites post-funding was higher than the change at comparison sites by a factor of 3.38 (p = 0.004, 95% CI: 1.51-7.57). An estimated 602 additional African American participants were recruited at MREG sites due to MREG funding, contributing to the overall 14.9% African American recruitment. Successful recruitment strategies most reported by MREG sites included increasing staff, transportation resources, recruiting through the media, mailings, and prostate cancer screening clinics during off-hours. LIMITATIONS: Comparison sites were chosen retrospectively, not by randomization. Although comparison sites were selected to be similar to MREG sites with regard to potential confounding factors, it is possible that unknown factors could have biased results. Cost-effective analyses were not conducted. CONCLUSIONS:MREG sites increased African American accrual in the post-funding period more than comparison sites, indicating MREG funding enhanced the sites' abilities to accrue African American participants. Targeted grants early in the accrual period may be a useful multi-site intervention to increase African American accrual for a prevention study where adequate African American representation is essential.
Authors: C M Moinpour; J O Atkinson; S M Thomas; S M Underwood; C Harvey; J Parzuchowski; L C Lovato; A M Ryan; M S Hill; E Deantoni; E R Gritz; I M Thompson; C A Coltman Journal: Ann Epidemiol Date: 2000-11 Impact factor: 3.797
Authors: Elise D Cook; Sarah Moody-Thomas; Karen B Anderson; Russell Campbell; Sandra J Hamilton; Joseph M Harrington; Scott M Lippman; Lori M Minasian; Electra D Paskett; Stephen Craine; Kathryn B Arnold; Jeffrey L Probstfield Journal: Clin Trials Date: 2005 Impact factor: 2.486
Authors: Eugene Z Oddone; Maren K Olsen; Jennifer Hoff Lindquist; Melinda Orr; Ronnie Horner; Domenic Reda; Philip Lavori; Gary Johnson; Joseph Collins; John R Feussner Journal: Control Clin Trials Date: 2004-08
Authors: Melissa A Green; Margo Michaels; Natasha Blakeney; Adebowale A Odulana; Malika Roman Isler; Alan Richmond; Debra G Long; William S Robinson; Yhenneko J Taylor; Giselle Corbie-Smith Journal: J Cancer Educ Date: 2015-03 Impact factor: 2.037
Authors: Kathryn B Arnold; John A Hermos; Karen B Anderson; Lori Minasian; Catherine M Tangen; Jeffrey F Probstfield; Elise D Cook Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-09-21 Impact factor: 4.254
Authors: Andrea M Denicoff; Worta McCaskill-Stevens; Stephen S Grubbs; Suanna S Bruinooge; Robert L Comis; Peggy Devine; David M Dilts; Michelle E Duff; Jean G Ford; Steven Joffe; Lidia Schapira; Kevin P Weinfurt; Margo Michaels; Derek Raghavan; Ellen S Richmond; Robin Zon; Terrance L Albrecht; Michael A Bookman; Afshin Dowlati; Rebecca A Enos; Mona N Fouad; Marjorie Good; William J Hicks; Patrick J Loehrer; Alan P Lyss; Steven N Wolff; Debra M Wujcik; Neal J Meropol Journal: J Oncol Pract Date: 2013-10-15 Impact factor: 3.840
Authors: Shiyu Jiang; Peng Liu; Sheng Yang; Jianliang Yang; Dawei Wu; Hong Fang; Yan Qin; Shengyu Zhou; Jianping Xu; Yongkun Sun; Hongnan Mo; Lin Gui; Puyuan Xing; Bo Lan; Bo Zhang; Le Tang; Yan Sun; Yuankai Shi Journal: BMJ Open Date: 2019-06-01 Impact factor: 2.692